Ignite Creation Date:
2025-12-24 @ 12:03 PM
Ignite Modification Date:
2026-02-25 @ 8:50 PM
Study NCT ID:
NCT02394561
Status:
COMPLETED
Last Update Posted:
2019-04-23
First Post:
2015-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04-10
Start Date Type:
ACTUAL
Primary Completion Date:
2017-06-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-06-08
Completion Date Type:
ACTUAL
First Submit Date:
2015-02-25
First Submit QC Date:
None
Study First Post Date:
2015-03-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-06-07
Results First Submit QC Date:
None
Results First Post Date:
2019-04-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-21
Last Update Post Date:
2019-04-23
Last Update Post Date Type:
ACTUAL